{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:1548972",
      "entity_text" : "fluvastatin",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:9606" ],
      "TissueType" : [ "tissuelist:TS-0800" ]
    }
  },
  "verbose_text" : "Genotyping for the above described polymorphisms in CYP2C9 revealed that the patient was heterozygous for CYP2C9 * 3 allele, suggesting that the patient carries a predisposition for higher fluvastatin plasma levels, which could contribute to increased susceptibility for adverse side effects.",
  "reading_complete" : "2020-08-03T19:49:32Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T19:45:28Z",
  "trigger" : "levels",
  "evidence" : [ "fluvastatin plasma levels" ],
  "pmc_id" : "4192324",
  "score" : 0
}